ACE in Ischemic Heart Disease

Ischemic heart disease: the next target for the angiotensin-converting enzyme inhibitors
S. Yusuf, E. Lonn

Is bradykinin important for the clinical outcome?
T. Bachetti

Is the endothelium an important therapeutic target?
R. Busse, I. Fleming

ACE inhibition in ischemic heart disease: what is the relevance of the control of the neuroendocrine response?
W.J. Remme

Surfing the Heart: European Agency for the Evaluation of Medicinal Products; Centers for Disease Control and Prevention; The Internet Drug Index; Reuters Health
C. Ceconi
Icons of Cardiology: Starling’s other observations
A.M. Katz

R.A. Lawrance, H. White, A.S. Hall

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
M.H. Alderman and others

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
S. Yusuf and others

The emerging concept of vascular remodeling
G.H. Gibbons, V.J. Dzau

Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection
E.M. Lonn and others

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival And Ventricular Enlargement trial
J.D. Rutherford and the SAVE Investigators

Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
F. Diet and others

Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND Study
G.B. Mancini and others

Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators
D.E. Vaughan and others

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials
The ACE Inhibitor Myocardial Infarction Collaborative Group

Angiotensin-converting enzyme inhibitors
N.J. Brown, D.E. Vaughan